Keywords autologous platelet transfusion, epidermal growth factor, platelet derived growth factor AIMS Topical growth factors accelerate wound healing in patients with diabetic foot ulcers (DFU). Due to the absence of head-to-head comparisons, we carried out Bayesian network meta-analysis to compare the efficacy and safety of growth factors.
Introduction
Diabetic foot ulcer (DFU) is a full-thickness wound involving dermis in either ankle or foot [1] with a 25% lifetime risk [2] . DFU is associated with significant morbidity and the mortality ranges between 4 and 10% [3, 4] . Further, the risk of amputation was between 0.06 and 3.83 per 1000 diabetics in developed countries [5] and a recurrence rate of 50% [6] . Management of DFU incurs significant financial burden amounting to 45 000 USD per patient [7] .
Management of DFU includes wound debridement, offloading the ulcer area using casts, extracellular matrix protein extracts, bio-engineered skin substitutes, negative pressure wound therapy, hyperbaric oxygen and growth factors such as platelet derived growth factor, epidermal growth factor and fibroblast growth factor [8] . These growth factors serve as the principal immediate mediators of wound healing [9] . Several randomized controlled trials confirmed the efficacy of each of the above-mentioned agents. The only metaanalysis comparing growth factors in DFU from Cochrane concluded that the use of growth factors improved wound healing compared to standard of care alone [10] . However, due to the absence of head-to-head clinical trials comparing all the different types of available growth factors, the authors did not attempt to evaluate the differences on determine which one was superior. Hence, we conducted the present network meta-analysis to compare the efficacy of various growth factors used topically in the management of DFU.
Methods

Information sources and search strategy
The protocol for this review was registered with PROSPERO with the registration number CRD 42016053523 on 23 December 2016. A thorough literature search was completed on 25 December 2016 with the detailed search strategy available in Figure S1 of the supporting information. Databases searched for potential articles included Medline (through PubMed), Cochrane CENTRAL and Google Scholar. No limits were placed with respect to either language or year of publication. References from screened literature were also searched for eligible studies.
Selection criteria
We included randomized controlled trials comparing growth factors for DFU. Those studies that included patients with infected DFU or complicated with osteomyelitis were excluded as were the studies comparing growth factors with skin substitutes. If the studies had additional arms that received interventions other than growth factors, the data pertaining to the growth factor and placebo or standard of care arms were considered. Similarly, for the studies that had several arms receiving different doses of the same growth factor, data from the arm with the highest dose was included. Studies were to be included if they provided data on the outcome measures, number of patients achieving complete healing (primary outcome) or adverse events (secondary outcomes).
Study procedure
Two authors independently performed a literature search in the above-mentioned databases. A pre-tested data extraction form was created and both authors independently extracted the following data from each eligible study: trial site, year, trial methods, participants, interventions and outcomes. Disagreement between the authors was resolved through discussion. The present review and network meta-analysis has been reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [11] .
Statistical considerations
We assessed the risk of bias of the included studies using the Cochrane risk of bias tool under seven domains for all the eligible studies [12] . A random effects model was used for both direct and indirect comparisons as this has limited assumptions and is more robust compared to a fixed effects model. The direct comparisons were performed using Revman 5.3 following heterogeneity assessment using Chi-squared and I 2 tests. We used a logistic regression model with the logit link function and binomial likelihood and chose to present the results as odds ratios (OR) for these models so as to avoid the ceiling effect that limits relative risks for outcomes with proportions around 0.8-0.95. NetMetaXL [13] and WinBUGS statistical analysis program version 1.4.3 (MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK) were used for generating results as the pooled estimates were obtained by means of the Markov chain Monte Carlo simulation method. We evaluated the sensitivity of the network to individual trials. We removed each trial one at a time and investigated the impact on the probability of which growth factor was 'best'. We also excluded trials that measured the outcome at 20 weeks and intended to do a sensitivity analysis by excluding trials with a high risk of bias in at least one domain. Inconsistency between direct and indirect comparisons was evaluated by plotting the posterior mean deviance of individual data points for consistency and inconsistency [13] . A step plot was used to compare treatment arms and a cumulative rankogram was generated based on the surface under cumulative ranking curve (SUCRA) [14] . Under a Bayesian approach, SUCRA estimates the probability of a treatment being the best. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) working group approach was used to assess the quality of evidence [12] . A probability of ≤0.05 was considered significant and no adjustments were made to multiple comparisons.
Results
Search results
A total of 837 articles were obtained of which 26 were found to be eligible to be included for final analysis (Figure 1 ). There were a total of 2088 participants with 1018 events from all these eligible studies. Direct data with pairwise comparisons was available for eight studies. All studies except one compared the effects of adjuvant growth factors with standard of care. Ten eligible studies were obtained evaluating recombinant human platelet-derived growth factor (rhPDGF), six assessed recombinant human epidermal growth factor (rhEGF), five compared autologous platelet rich plasma (PRP), three evaluated recombinant human basic fibroblast growth factor (two compared with standard of care and one with recombinant human acidic fibroblast growth factor) and one each with recombinant human vascular endothelial growth factor (rhVEGF) and recombinant human transforming growth factor beta (rhTGFβ). Network diagram is depicted in Figure 2 . Key details of the individual studies are summarized in Table S1 of the supporting information. A summary of risk of bias of the included studies is depicted in Figure 3 . We observed high risk of bias with respect to random sequence generation, allocation concealment and blinding in five studies. Four studies had detection bias, seven reported incomplete outcomes and 13 had selective reporting bias. Six studies had other biases in terms of imbalances in the demographic variables, failure to report baseline characteristics of the study participants and funding.
Pooled results
Primary outcome Direct comparisons. All except one of the direct comparisons were performed between growth factors and standard of care. Only one study compared the efficacy of Figure 1 Study flow diagram. A total of 26 studies were found eligible to be included from 837 articles that were obtained with the search strategy Figure S5 ). The pooled estimates (Odds ratio [95% confidence interval]) for the direct comparisons revealed that rhPDGF, autologous PRP and rhEGF were associated with higher odds of complete healing against standard of care (Table 1) . Only one study was obtained for each of the factors, talactoferrin, rhVEGF, rhTGFβ and rhaFGF, and so pooling of the results could not be attempted.
Mixed treatment comparisons. Comparisons of the efficacy between the interventions indirectly through a common comparator were performed. A statistically significant increase in the number of individuals with complete healing was observed with rhEGF, rhPDGF and autologous PRP when compared with standard of care (Table 1) . Additionally, rhEGF was observed to be better than autologous PRP, rhPDGF, rhbFGF and rhTGFβ. Similarly, rhPDGF and autologous PRP significantly improved the outcome measure when compared with rhTGFβ. The consistency between the pooled estimates of indirect and available direct comparisons is illustrated in Table 1 . Recombinant human epidermal growth factor was observed to perform better than other factors (Table 1) . This is also substantiated by SUCRA (Figure 4 ). We observed a high probability for rhEGF to be the best growth factor for complete healing in DFU. No inconsistencies were observed between the direct and indirect comparisons ( Figure S6 ).
Sensitivity analysis. Sensitivity analyses were performed 26 times, of which 25 involved eliminating each trial one at a time. The outcomes were analysed at 12 weeks in seven studies [16, 20, 21, 24, 26, 32, 35] , at 20 weeks in six studies [28, 29, 33, 34, 37, 39] , four studies [18, 23, 25, 30] measured at 8 weeks, three studies [15, 19, 36] measured at 10 weeks and one each at 4, 5, 6, 15, 16 and 24 weeks. Analysis was also performed by excluding data from studies that measured the outcome at 20 weeks as was carried out in the previous Cochrane review. At each analysis, we evaluated the factor that performed best as per SUCRA as well as the pooled effect estimates. Subsequently rhEGF was found to have the maximum probability of being the best. Regarding the pooled estimates, the results of the sensitivity analyses largely agreed with that of the main results, despite small numerical differences between both analyses. With regard to eliminating six studies that assessed the outcomes at 20 weeks, rhEGF had the highest probability of being the best intervention. The sensitivity analyses confirmed that none of the individual studies had a biased effect on both the effect estimates of the comparisons and ranking of treatment arms. Sensitivity analyses could not be carried out for direct comparisons excluding trials with high risk of bias as there were a total of 18 studies with high risk in at least one domain. Secondary outcomes (safety analysis). The total number of adverse events reported in each study was pooled for each growth factor. We included data from 11 studies with 1474 participants (four in rhPDGF, three with autologous PRP, two with rhEGF and one each with rhVEGF and talactoferrin) that reported wound infection, cellulitis, osteomyelitis, skin ulceration and peripheral oedema. Sub-
Figure 2
Network diagram rhPDGF, recombinant human platelet derived growth factor; PRP, platelet rich plasma; rhEGF, recombinant human epidermal growth factor; TGFβ, transforming growth factor beta; rhVEGF, recombinant human vascular endothelial growth factor; rhbFGF, recombinant human basic fibroblast growth factor; rhaFGF, recombinant human acidic fibroblast growth factor. Large majority of studies compared rhPDGF followed by rhEGF with standard of care
Growth GRADE. Grading the quality of evidence was carried out separately for direct and indirect comparisons (Tables 3 and 4 ). The quality of evidence for most of the comparisons evaluated in the present study was observed to be low due to serious imprecision and indirectness of the estimates. For few comparisons, the quality of evidence was observed to be very low thus expressing uncertainty. Evidence for adverse events was very low due to serious limitations in consistency, indirectness and imprecision. Additionally, we could not assess the quality of evidence for adverse events to talactoferrin as there was only one study included in this review and no adverse events were observed.
Discussion
We conducted the present Bayesian network meta-analysis to identify the effect of different growth factors in healing of DFU. A total of 26 studies involving 2088 participants with 1018 events were included. The results of the study should be carefully interpreted considering the high risk of bias observed in most of the included studies. Only three growth factors, namely rhEGF, rhPDGF and autologous PRP, were found to be better than standard of care. Additionally, rhEGF was found to be better than autologous PRP, rhPDGF, rbFGF and rhTGFβ and both autologous PRP and rhPDGF were found to be better than rhTGFβ. We also observed that rhEGF has the highest probability of being the best growth factor for the treatment of DFU and was significantly associated with a higher proportion of complete healing with standard of care, rhPDGF, autologous PRP, rhbFGF and rhTGFβ. No significant differences in the risk of adverse events were observed in the pooled analyses by indirect comparisons. However, direct comparisons revealed minor reduction in the risk of lower limb amputation. This is the first network meta-analysis to analyse the efficacy of various growth factors used topically for the treatment of DFU. A network meta-analysis offers the advantage of comparison between multiple treatments not only directly but also indirectly using a common comparator [41] . This is Figure 3 Summary of risk of bias of the included studies. This indicates that the majority of the studies have either an unclear or a high risk in most of the elements Table 1 Point estimate (odds ratio) with 95% credible intervals for the mixed treatment comparisons and odds ratio with 95% confidence intervals for the direct comparisons Direct data are presented in the form of odds ratio (95% confidence interval) and MTC data are presented in the form of odds ratio (95% credible intervals).
*P ≤ 0.05 rhEGF, autologous PRP and rhPDGF were observed with better healing response than standard of care alone both by direct and mixed treatment comparison analyses.
especially used in head-to-head comparisons with a common comparator. To discuss with a simple example, when there are three treatment arms, A, B and C, and when head-tohead trials have been conducted only between A and B and B and C, indirect comparisons between A and C can be made through the common comparator B. By doing so, it may be possible to identify the best among a basket of agents that can be used for treating a particular disease in the case of limited clinical evidence [42] . The conclusion of a Cochrane review on a similar topic was based on the use of autologous PRP or rhPDGF with little information on rhEGF [10] . The review included head-to-head trials that compared growth factors to either placebo or standard of care. Hence, there was no inference from the review regarding the superiority of growth factors. Growth factors play a significant role in angiogenesis, enzyme production, cell migration and proliferation [43] . EGF has been shown to stimulate epidermal and dermal repair in animal wound models [44] . Deep injection of EGF into the ulcer stimulates the production of extracellular matrix proteins thereby enhancing cell proliferation and migration [45] . A meta-analysis specifically evaluating the effects of rhEGF in DFU corroborated with the findings of the present network meta-analysis [46] . Topical use of growth factors was observed to reduce the incidence of lower limb amputation. Studies suggest good tolerability profile with frequent adverse events that include burning sensation, tremor, chills and local pain [47] . This is also confirmed by a prospective, active post-marketing surveillance study in 41 hospitals and 19 primary care polyclinics wherein 1835 DFU patients on rhEGF were evaluated [48] . However, the safety results from this review should be considered as preliminary evidence because of limited data precluding firm conclusions. Further, the quality of evidence for adverse event outcomes for growth factors in the present review was graded very low due to serious limitations in terms of inconsistency, indirectness and imprecision.
Multi-disciplinary approaches are essential for the management of any wound, particularly DFU. Wound debridement, removal of necrotic tissue and infection control are Evaluation of rankogram by SUCRA estimates. Rankogram assessment indicates a high probability for rhEGF to be the 'best' in the pool Table 2 Pooled estimates for the secondary outcome measures for adjuvant growth factors difference in clinically significant effect size between the agents [49] . The strength of the present review is that this is the first evidence comparing the efficacies and safety of various growth factors, albeit indirectly. From a clinical standpoint, it might take years to generate real-time evidence based on clinical trials. Secondly, we also found that both rhPDGF and autologous PRP tend to be more efficacious than standard of care when trials that assessed the outcome at 20 weeks were included. Future studies should explore the temporal relationship of the wound-healing effects of these growth factors. However, the results should be interpreted considering the variations in the duration of ulcer, standard of care, administration of antimicrobial agents and anti-diabetic drugs that were administered to the study participants. Also, this review excluded patients with infected DFU or DFU complicated with osteomyelitis. Eighteen studies in the present review had high risk of bias in one or more elements. Authors of future studies should take care in eliminating or reducing systematic errors in all domains to generate high quality evidence. Another limitation of the study is the low quality of evidence for most of the comparisons and that we did not search EMBASE due to access constraints.
To conclude, adjuvant topical rhEGF, rhPDGF and autologous PRP were found to be more beneficial than standard of care and rhEGF might be the best growth factor in the pool. However, the results should be interpreted with extreme caution as the results might change with the publication of headto-head studies in future.
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